Clinical Trials Logo

Clinical Trial Summary

The aim of the present study was therefore to evaluate if the perioperative administration of symbiotics reduces postoperative infectious morbidity in jaundiced patients scheduled for hepato-biliary and pancreatic surgery.


Clinical Trial Description

Despite advances in preoperative patient's selection and anesthetic and surgical techniques, surgery in jaundiced patients is associated with significant morbidity and mortality as a consequence of septic complications. The evidence that nosocomial infections are frequently a consequence of gut-derived organism such as enterobacteriaceae, supports the hypothesis of the "gut derived sepsis". Indeed, several studies have reported that jaundiced patients present an increased intestinal permeability and consequently a higher rate of bacterial migration from gastrointestinal tract across the lamina propria to local mesenteric lymph nodes and from there to extra-intestinal site. This phenomenon increases after surgical decompression of bile duct. The higher prevalence of bacterial translocation in jaundiced patients is related to different mechanisms such as mucosal atrophy secondary to protracted absence of intraluminal bile that open para-cellular route for bacterial translocation and the decreased clearance capacity of Kuppfer secondary to cholestasis.

The mechanisms of action of symbiotics are largely unknown. The probiotic bacteria can improve the mucosal barrier function reducing the bacterial translocation of organism to mesenteric lymph nodes. Indeed symbiotic can affect the intestinal ecosystem by stimulating mucosal immune and non-immune mechanisms through antagonism/competition with potential pathogens. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01683708
Study type Observational
Source Azienda Ospedaliera Ordine Mauriziano di Torino
Contact
Status Active, not recruiting
Phase N/A
Start date November 2008

See also
  Status Clinical Trial Phase
Completed NCT00383318 - Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Withdrawn NCT04021927 - Development of a Neonatal Jaundice Treatment Accelerator by Redirection of Unused Light During Phototherapy N/A
Completed NCT00966719 - Breastfeeding Support Intervention in Jaundiced Infants N/A
Completed NCT02033096 - Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
Terminated NCT01514058 - A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction N/A
Completed NCT01203410 - Prediction of Jaundice in Term Infants
Not yet recruiting NCT06232174 - Value of Transcutaneous Bilirubin Devices
Completed NCT01356030 - Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer N/A
Not yet recruiting NCT06276738 - The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
Completed NCT02991339 - The Effects of Dexamethasone Administration on Jaundice Following Liver Resection Phase 2/Phase 3
Completed NCT02787512 - Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer N/A
Withdrawn NCT00240123 - Effect of Benadryl Sedation During ERCP or EUS Phase 1
Completed NCT02926131 - A Study to Evaluate a New Jaundice Stick Test
Completed NCT01499537 - Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct N/A
Active, not recruiting NCT02376907 - Biliary Drainage in Patients With Duodenal Metal Stent N/A
Terminated NCT01887041 - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer Phase 4
Recruiting NCT06173947 - SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
Active, not recruiting NCT04271176 - Jaundice as Initial Presentation of Liver Hydatidosis (ICTEHIDA)
Completed NCT01976936 - Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 Phase 2